Adagio Therapeutics

invivyd, inc. (nasdaq: ivvd) is a commercial-stage company is a biopharmaceutical company on a mission to deliver protection from serious viral infectious diseases, beginning with sars-cov-2. leveraging state-of-the-art viral surveillance, predictive modeling, and advanced antibody engineering techniques, we are taking a platform-based approach to the continuous discovery and optimization of monoclonal antibody candidates designed to protect the vulnerable from serious viral threats. in march 2024, invivyd received emergency use authorization (eua) from the u.s. fda for its first mab in a planned series of innovative antibody candidates. visit https://invivyd.com/ to learn more.